Clinical Trials · NCT01512108
Safety and Efficacy of Liraglutide in Combination With an OAD in Subjects With Type 2 Diabetes Insufficiently Controlled on OAD Alone
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 363
- Start date
- Jan 2012
- Locations
- 36 sites, Japan
- Primary endpoint
- Incidence of Treatment Emergent Adverse Events (AEs)